Clinical Trial Update: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating belzutifan (MK-6482) in combination with fulvestrant for ER+/HER2- metastatic breast cancer is currently recruiting under the LITESPARK…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Welireg (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Breast Cancer | Phase 2 | Status: RECRUITING